Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 23, Number 7—July 2017
Research

MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015

Pyoeng Gyun Choe1, R.A.P.M. Perera1, Wan Beom Park, Kyoung-Ho Song, Ji Hwan Bang, Eu Suk Kim, Hong Bin Kim, Long Wei Ronald Ko, Sang Won Park, Nam-Joong Kim, Eric H.Y. Lau, Leo L.M. Poon, and Myoung-don OhComments to Author 
Author affiliations: Seoul National University College of Medicine, Seoul, South Korea (P.G. Choe, W.B. Park, K.-H. Song, J.H. Bang, E.S. Kim, H.B. Kim, S.W. Park, N.-J. Kim, M.-D. Oh); University of Hong Kong School of Public Health, Hong Kong, China (R.A.P.M. Perera, L.W.R. Ko, E.H.Y. Lau, L.L.M. Poon, M. Peiris)

Main Article

Table

Characteristics and serologic responses of patients from MERS-CoV outbreak by time after disease onset, South Korea, 2015*

Pt.
 Severe disease
 Peak viral load†
 Corticosteroid use
 Titers and ODs at various time points after disease onset
PRNT90 antibody titer MERS-CoV spike ppNT Microneutralization assay titer MERS-CoV S1 ELISA OD‡
21–50 d
 180–248 d§
 285–403 d§
21–50 d
 180–248 d
 285–403 d
21–50 d
 180–248 d
 285–403 d
21–50 d
 180–248 d
 285–403 d
C Yes 6.1 No 640 160 (216 d) 80 (332 d) 640 160 80 320 160 40 6.2 2.9 2.5
D Yes 8.2 Yes (11–23) ¶ 160 80 (181 d) 80 (294 d), 80 (397 d) 160 160 80 80 80 80 2.6 3.0 2.5
F Yes 4.8 Yes (14–16) ¶ 320 80 (248 d) 80 (312 d), 80 403 d) 320 320 40 160 40 40 3.6 1.7 1.5
G Yes 7.2 No 80 80 (219 d) 80 (358 d) 80 80 160 80 80 80 3.4 2.9 2.5
I Yes 5.2 No NA# 80 (180 d) 80 (298 d), 40 (370 d) 40 40 40 40 40 40 1.1 2.4 1.6
K No 6.7 No 80 NA 40 (420 d) 160 NA 40 40 NA 20 1.7 NA 1.1
L No 4.6 No <10 10 (192 d) 10 (285 d), 10 (403 d) 10 <10 <10 <10 <10 <10 1.0 0.3 0.4
M No 5.4 No NA** <10 (209 d) <10 (296 d), <10 (394 d) <10 <10 <10 <10 <10 <10 0 0.1 0.1
N No 6.6 No 80 40 (220 d) 40 (296 d), 40 (394 d) 40 80 40 80 40 20 4.1 1.6 1.4
O No 8.2 No NA 10 (218 d) 10 (294 d), 10 (379 d) NA <10 10 NA <10 <10 NA 0.6 0.5
P No 5.5 No 10 <10 (212 d) <10 (290 d), <10 (386 d) <10 <10 <10 <10 <10 <10 0.3 0.1 0.1

*MERS-CoV, Middle East respiratory syndrome coronavirus; NA, not assayed; OD, optical density; ppNT, pseudoparticle neutralization test; PRNT90, >90% plaque-reduction neutralization test; Pt., patient; S1, spike protein; upE, region upstream of the E gene.
†Viral loads (log10 upE RNA copies/mL) were quantified from sputum samples.
‡MERS-CoV S1 ELISA OD ratios <0.8 were considered negative, ≥0.8 to <1.1 were considered borderline, and ≥1.1 were considered positive.
§Exact day(s) after disease onset that serum was collected are indicated in parentheses.
¶Days after disease onset during which corticosteroids were used.
#PRNT90 antibody titer was 40 on day 18.
**PRNT90 antibody titer was 10 on day 16.

Main Article

1These authors contributed equally to this article.

Page created: June 19, 2017
Page updated: June 19, 2017
Page reviewed: June 19, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external